No connection

Search Results

ABBV vs HQY

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
HQY
HealthEquity, Inc.
NEUTRAL
Price
$77.96
Market Cap
$6.66B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ABBV
163.63
HQY
31.69
Forward P/E
ABBV
15.42
HQY
14.6
P/B Ratio
ABBV
-146.66
HQY
3.15
P/S Ratio
ABBV
6.5
HQY
5.07
EV/EBITDA
ABBV
15.27
HQY
15.08

Profitability

Gross Margin
ABBV
71.46%
HQY
69.52%
Operating Margin
ABBV
35.5%
HQY
21.64%
Profit Margin
ABBV
4.0%
HQY
16.38%
ROE
ABBV
137.96%
HQY
10.19%
ROA
ABBV
9.59%
HQY
5.99%

Growth

Revenue Growth
ABBV
9.1%
HQY
7.3%
Earnings Growth
ABBV
-88.7%
HQY
92.4%

Financial Health

Debt/Equity
ABBV
--
HQY
0.48
Current Ratio
ABBV
0.72
HQY
3.27
Quick Ratio
ABBV
0.47
HQY
2.82

Dividends

Dividend Yield
ABBV
3.05%
HQY
--
Payout Ratio
ABBV
490.15%
HQY
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
HQY NEUTRAL

HQY presents a stark divergence between strong fundamental earnings performance and bearish market sentiment. The company maintains a stable financial health profile with a Piotroski F-Score of 4/9 and excellent liquidity (Current Ratio 3.27). While the current price of $77.96 trades at a premium to its intrinsic value ($72.57) and Graham Number ($37.04), the Forward P/E of 14.60 suggests significant expected earnings expansion. However, the bullish fundamental outlook is heavily countered by a 0/100 technical trend and consistent insider selling.

Strengths
Explosive YoY earnings growth of 92.40%
Strong liquidity position with a current ratio of 3.27
Impressive gross margins of 69.52%
Risks
Strongly bearish technical trend (0/100)
Net insider selling activity across multiple executives
Current price exceeds growth-based intrinsic value ($72.57)

Compare Another Pair

ABBV vs HQY: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and HealthEquity, Inc. (HQY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile